Oestrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin‐1

Lee, TM; Sf, Su; Ch, Tsai

doi:10.1046/j.1365-2362.2002.00961.x

Cited by 9 publications

(7 citation statements)

References 30 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The increased levels of ET-1 released into the coronary sinus during coronary angioplasty can be blunted by administration of estrogen. 4 The present results were compatible with previous findings that showed that ET-1 production was inhibited by a physiological concentration of estrogen via an estrogen receptor-independent mechanism, an effect detectable as early as 20 minutes after intracoronary infusion. [27][28][29] …”

Section: Vascular Protectionsupporting

confidence: 93%

“…We have demonstrated that endothelin-1 (ET-1) plays an important role in coronary vasoconstriction after angioplasty. 4 A specific antagonist of the ET A receptor (BQ123) has been shown to attenuate coronary vasoconstriction in experimental and clinical studies. 5,6 We have demonstrated that estrogen is cardioprotective against infarct of any size and myocardial ischemia by activation of ATP-sensitive potassium (K ATP ) channels in animals 7,8 and in humans, 9 similar to ischemic preconditioning (IP).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

2003

View full text Add to dashboard Cite

Background-We have demonstrated that estrogen can reduce myocardial injury in ischemia-reperfusion via activation of ATP-sensitive potassium (K ATP ) channels. We sought to determine whether the protective effect of estrogen extends to epicardial coronary artery with attenuated vasoconstriction in patients after angioplasty by activation of such channels. Methods and Results-The study was designed to prospectively investigate 41 consecutive patients scheduled for elective coronary angioplasty. Pretreatment with estrogen limited myocardial ischemia during coronary occlusion and attenuated postangioplasty coronary vasoconstriction at the dilated and distal segments. An inhibitor of K ATP channels, glibenclamide, did not affect coronary vasomotor response, although it abolished the beneficial effect of estrogen on myocardial ischemia. Patients to whom estrogen was administered after the second balloon deflation experienced a similar magnitude of myocardial ischemia as controls but showed significantly attenuated vasoconstriction compared with controls (Pϭ0.0001). Endothelin-1 levels from the great cardiac vein rose significantly from 1.9Ϯ0.4 to 3.1Ϯ0.6 pg/mL (Pϭ0.001) 15 minutes after angioplasty in the control group; this was attenuated after estrogen was administered. Significant correlation was found between the changes in coronary vasomotion of the dilated segment and endothelin-1 levels (rϭ0.65, PϽ0.0001). Conclusions-These results demonstrate that estrogen is protective against both myocardial ischemia and coronary vasoconstriction through different mechanisms. The myocardial effect of estrogen was abolished by glibenclamide, which suggests that the cardioprotective effect of estrogen may result from activation of K ATP channels. In contrast, estrogen-induced attenuated vasoconstriction is associated with an attenuated release of endothelin-1, independent of K ATP activation.

show abstract

Section: Vascular Protectionsupporting

confidence: 93%

mentioning

confidence: 99%

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

2003

View full text Add to dashboard Cite

show abstract

“…Plasma and urinary samples for ET-1 measurements were collected and extracted as previously described [21]. Samples were immediately centrifuged at 3000 Â g for 10 min, and the plasma samples were stored at À708C until further analysis.…”

Section: Laboratory Testsmentioning

confidence: 99%

Effect of nicorandil on proteinuria in well controlled hypertensive patients

Lee

Chang

2009

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…14 Plasma and urinary samples for ET-1 measurements were collected and extracted as previously described. 15 Samples were immediately centrifuged at 3000g for 10 minutes, and the plasma was stored at Ϫ70°C until further analysis. ET-1 was measured by immunoassay (R&D System Inc).…”

Section: Laboratory Testsmentioning

confidence: 99%

Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension

2002

View full text Add to dashboard Cite

Abstract-Proteinuria is an important risk factor for cardiovascular and renal morbidity and mortality. The effects of 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor (statin) therapy on proteinuria in normolipidemic patients with well-controlled hypertension have not been studied. A total of 63 normolipidemic (total cholesterol Ͻ240 mg/dL) and proteinuric (300 to 3000 mg/d) patients with well-controlled blood pressure (Ͻ140/90 mm Hg) were randomized to receive either placebo (nϭ32) or pravastatin (10 mg/d; nϭ31) after a 3-month placebo period. Pravastatin lowered proteinuria after 6 months by 54% (PϽ0.0001). Creatinine clearance was stable throughout the study in the 2 groups. Despite unchanged plasma endothelin-1 levels throughout the study, urinary excretion of the peptide was decreased and significantly correlated with improvement in urinary protein excretion in pravastatin-treated patients (rϭ0.64, Pϭ0.001). The urinary excretion of retinol-binding protein decreased after pravastatin administration, probably reflecting an improvement in tubular function. In contrast, the urinary excretion of IgG did not change significantly throughout the study in either group. Multivariate analysis revealed that proteinuria was only significantly correlated with statin use (PϽ0.0001, R 2 ϭ0.66). Linear regression analysis in the statin-treated group did not show any correlation between changes in lipid profiles and proteinuria regression. Thus, in addition to their primary function of antilipidemia, the addition of pravastatin to treatment for well-controlled hypertension may have an additive effect on reducing proteinuria independent of hemodynamics and lipid-lowering effects, possibly through inhibiting renal endothelin-1 synthesis and improving tubular function.

show abstract

Oestrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin‐1

Cited by 9 publications

References 30 publications

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

Effect of nicorandil on proteinuria in well controlled hypertensive patients

Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension

Contact Info

Product

Resources

About

Oestrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin‐1

Cited by 9 publications

References 30 publications

Differential Role of K ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

Differential Role of K ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

Effect of nicorandil on proteinuria in well controlled hypertensive patients

Effect of Pravastatin on Proteinuria in Patients With Well-Controlled Hypertension

Contact Info

Product

Resources

About

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects

Differential Role of K _ATP Channels Activated by Conjugated Estrogens in the Regulation of Myocardial and Coronary Protective Effects